Loading...
Market
Leading drug for primary biliary cholangitis by June 2025
5
Resolution / Starting Odds
Iqirvo • 33%
Intercept Pharmaceuticals • 33%
Other • 34%
Market share reports from industry analysts
Story
Ipsen and Genfit's Iqirvo Receives Accelerated FDA Approval for Rare Liver Disease After Eight Years
Jun 10, 2024, 10:45 PM
Ipsen and Genfit have received accelerated approval from the U.S. Food and Drug Administration (FDA) for their new drug, Iqirvo, which treats primary biliary cholangitis, a rare chronic inflammatory liver disease. This marks the first new treatment option for the disease in eight years. The approval sets the stage for a potential market competition with Intercept Pharmaceuticals.
View original story
Similar markets
Viking Therapeutics • 33%
Madrigal Pharmaceuticals • 33%
GPCR • 33%
Q3 2024 • 25%
Q4 2024 • 25%
H1 2025 • 25%
H2 2025 • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Merck • 25%
Yes • 50%
No • 50%
Remains focused solely on liver diseases • 33%
Expands to include other organ-specific diseases • 33%
Expands to include systemic diseases • 33%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
Eylea retains majority market share • 50%
Biosimilars gain majority market share • 50%
